Essential (primary) hypertension
Conditions
Interventions
This is a randomised, placebo-controlled clinical trial. Experimental group: 60 patients with high blood pressure will receive 2 sachets of probiotics (a mixture of Lactobacillus acidophillus, Lactoba
G07.203.300.456
Sponsors
Universidade Federal da Paraíba
Universidade Federal da Paraíba
Eligibility
Age
20 Years to 59 Years
Inclusion criteria
Inclusion criteria: Hypertensive volunteers; both sexes; non-smokers; aged between 20 and 59 years; diagnosed with arterial hypertension for more than one year
Exclusion criteria
Exclusion criteria: Pregnant or breastfeeding women; smoking; kidney failure; dialysis; heart disease; stroke; or heart disease; stroke; autoimmune disease; and the presence of any other medical condition that may interfere with compliance with the with the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that the composition and diversity of the gut microbiota of patients with hypertension will improve, resulting in better cardiovascular, anthropometric, metabolic and inflammatory parameters compared to pre-intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected. | — |
Countries
Brazil
Contacts
Public ContactLudmilla Sales
Universidade Federal da Paraíba
Outcome results
None listed